Document 0589
 DOCN  M9480589
 TI    The genetic and functional basis of HIV-1 resistance to nonnucleoside
       reverse transcriptase inhibitors.
 DT    9410
 AU    Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV; Merck Research
       Laboratories, West Point, Pennsylvania.
 SO    Arch Virol Suppl. 1994;9:11-7. Unique Identifier : AIDSLINE MED/94305388
 AB    The nonnucleoside reverse transcriptase (RT) inhibitors are structurally
       diverse compounds that are specific inhibitors of the human
       immunodeficiency virus type 1 RT enzyme. The compounds are largely
       functionally identical and bind to a common site in the enzyme. HIV-1
       variants that exhibit reduced susceptibility to these inhibitors have
       been derived in cell culture and, more recently, from HIV-1-infected
       patients undergoing experimental therapy. The variants express amino
       acid substitutions at RT positions that apparently interact directly
       with the inhibitors. Effects of specific substitutions at these
       positions vary among the compounds, suggesting subtle differences in how
       the compounds physically interact with the enzyme.
 DE    Antiviral Agents/*PHARMACOLOGY  Benzodiazepines/PHARMACOLOGY
       Benzoxazoles/PHARMACOLOGY  Clinical Trials  Drug Resistance,
       Microbial/GENETICS  Human  HIV Infections/DRUG THERAPY  HIV-1/*DRUG
       EFFECTS/GENETICS  Imidazoles/PHARMACOLOGY  Pyridines/PHARMACOLOGY
       Pyridones/PHARMACOLOGY  Reverse Transcriptase/*ANTAGONISTS &
       INHIB/GENETICS  *Variation (Genetics)  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).